NeuroVive Pharmaceutical AB Shares outstanding
What is the Shares outstanding of NeuroVive Pharmaceutical AB?
The Shares outstanding of NeuroVive Pharmaceutical AB is 49.459M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Miscellaneous sector on LSE compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with shares outstanding similar to NeuroVive Pharmaceutical AB
- Regenxbio Inc has Shares outstanding of 49.423M
- Oncternal Therapeutics has Shares outstanding of 49.427M
- SKF India has Shares outstanding of 49.438M
- SKF India has Shares outstanding of 49.438M
- Knoll Inc has Shares outstanding of 49.441M
- California Resources Corp has Shares outstanding of 49.453M
- NeuroVive Pharmaceutical AB has Shares outstanding of 49.459M
- Navin Fluorine International has Shares outstanding of 49.495M
- News Invest has Shares outstanding of 49.545M
- Navin Fluorine International has Shares outstanding of 49.545M
- DoubleDown Interactive Co has Shares outstanding of 49.553M
- Prestige Consumer Healthcare Inc has Shares outstanding of 49.557M
- Beauce Gold Fields has Shares outstanding of 49.561M